RIGL 3.65 - Tue, April 13, 2021, 6:00 AM...Based on these data, Rigel plans to discuss the potential for emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA) of fostamatinib as a treatment for hospitalized patients with COVID-19.

https://finance.yahoo.com/news/positive-topline-data-shows-fostamatinib-110000249.html

SNFCA 8.52 - tripled down here this morning.

RIGL 3.27 - added here...Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021

https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14765212&RcvdDate=3/2/2021&CoName=RIGEL%20PHARMACEUTICALS%20INC&FormType=8-K&View=html

RIGL 3.27 - added here...Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021

https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14765212&RcvdDate=3/2/2021&CoName=RIGEL%20PHARMACEUTICALS%20INC&FormType=8-K&View=html

RIGL 3.27 - added here...Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021

https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14765212&RcvdDate=3/2/2021&CoName=RIGEL%20PHARMACEUTICALS%20INC&FormType=8-K&View=html

AATV .56 - Seems like things have dropped off. January revenues were only $600K. And they didn't announce February revenues...so I'm guessing they weren't great.

Putting the smell-test-debate aside for the moment, we know with some certainty that management delights in tooting their own 'revenue' horn...and you are correct...they ain't tooted that 'revenue' horn at all in the previous several pr's, including yesterday's pr.

https://finance.yahoo.com/news/adaptive-ad-systems-continues-aggressive-172000131.html

Sold my entire poke in the mid-.50's for a smallish gain and content to wait for some positive 'revenue' guidance...

Initial testing has already been done in Japan, the Phase I testing will satisfy US requirements, then we move on.

"...Estimated Primary Completion Date : January 30, 2023..."

https://clinicaltrials.gov/ct2/show/NCT04396717

Some here continue to post with the rosiest of eyeglasses...

SNFCA 9.55 - from the 10K...Provision for loan loss reserve: 16,506,030...and SNFCA still booked a 2.88 yearly eps. A few of the playuhs do seem to remain staring out the window on this one?

Scott Quist, Chairman of the Board, President, and Chief Executive Officer of SNFC, said, “For the year total revenues increased 94%, profitability increased over 400%, and we achieved a 21% return on equity. Those spectacular results, delivered in difficult circumstances, reflect the excellence of our Company and its people. I applaud the efforts of all our teams in their considerable accomplishment. Most importantly, every business segment delivered impressive results.

March 24, 2021 - ...Screening to enroll patients in the trial is already underway...

They couldn't have posted this in February as previously scheduled???

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162128055

Some management dementia tests do seem in order here no matter your trading preference, buy, hold or sell...

Why aren't we seeing any Form 4 filings showing some insiders buying such impressive numbers? Also, it would be nice to see some good faith effort made to rise above (uplisting...duh) the incessant pinksheet promiscuity...

SNFCA is right on time for a 12/31 year-end filing schedule. What's missing is they just don't say much, ever...

Sure looks like an uncontested layup to me. Don't see numbers like this in any $10 stock, and pound-for-pound, fundamental numbers unmatched in any stock?

SNFCA 9.40 - snagged a few more in this afternoon's weakness.

$1.51 EPS in Q3 - $2.68 EPS at 9 Months - EPS in Q4 due anyday is anyone's guess...

November 16, 2020 - Scott M. Quist, President of the Company, said, “For the quarter, revenues increased 94%, profitability increased 700%, and YTD we have a 26% return on equity. I believe our third quarter is the best operational third quarter ever for each of our business segments. Those are spectacular results that have been delivered in difficult circumstances. I applaud the efforts of all our teams in their considerable accomplishment. Every business segment delivered impressive results.

https://finance.yahoo.com/news/security-national-financial-corporation-reports-130000631.html

Maybe because the news was 26 days too late, ya think? My best guess is someone at the wheel is in a coma...

AATV .64 - it ran to a high of .95 on the 2/8/21 'Revenue' news...

February 8, 2021 - Revenue recorded for the fourth quarter of 2020 exceeded $5.71 million, for an increase of more than double from that prior largest quarter.

https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=aatv&insttype=&freq=1&show=&time=5

...now add to that this morning's reported quarterly 'EPS' number of '.0566' and I don't see why it shouldn't bust out out above $1...but...for the sleazy pinksheet market it resides in and management's contentment to continue operating in that rinkydinkystinkypinky arena?

Sure wish they'd discuss some desire to uplist...

AATV .46 - reports Q4 Revenue 5.8M / EPS .0566...

https://backend.otcmarkets.com/otcapi/company/financial-report/274924/content

AATV .46 - reports Q4 Revenue 5.8M / EPS .0566...

https://backend.otcmarkets.com/otcapi/company/financial-report/274924/content

You got me, why the executive silence I haven't the answer...

ODT 3.35 - with approx. $3.50 BV at 12/31/21 (mostly cash), I'm not seeing any dissolution in my crystal ball. From my experience, they'll likely announce a re-structuring to conserve cash while seeking new ventures ie: similar to another SPAC - with one huge advantage in the potential $366M "Accumulated Deficit" writeoff...

Accumulated deficit (366,427)

https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14733684&RcvdDate=2/23/2021&CoName=ODONATE%20THERAPEUTICS,%20INC.&FormType=10-K&View=html

Of note: a few years ago these biobusts would frequently dip down below cash but not so in this crazybonkers market...guessing they will again eventually...

Is it standard-operating-procedure of this company to proclaim in a cc:

Subsequent to year end, we raised over $43 million in gross proceeds from the sale of common stock and when factoring in an estimate of first quarter spending, we currently have approximately $56 million in cash on our balance sheet. This provides an operating runway through 2023 at our current cash usage of $4.5 million per quarter.

https://seekingalpha.com/article/4415104-celsion-corporation-clsn-ceo-michael-tardugno-on-q4-2020-results-earnings-call-transcript?amp=&utm_medium=referral&utm_source=dowjonesnewswire.com

And then dump a $100M ATM on we plebians immediately afterward??

https://www.otcmarkets.com/filing/html?id=14814603&guid=BMpaUnLBMuT6M3h

Well, Isn't that special...

SNFCA traded a 60k and a 30k block at 10.54 in the final minutes...

https://quotes.freerealtime.com/quotes/SNFCA/Time%26Sales

...someone else likes it.

SNFCA 10.54 - very strong close in the final minutes. Both price & volume. Don't see any news...

ENHT .004 / .0055 - is an old crusty stinkypinky shell that's been dormant for years. Trading at a $50K cap if the numbers are still correct...

AATV reports quarterly as a pinksheet...

https://www.otcmarkets.com/stock/AATV/disclosure

The "streaming tv" sector is on fire and these guys seem to have been involved in it for more than 15 years.

AATV .48 - Jun 05, 2007...J. Michael Heil, C.E.O. of Synergetic Technologies, said, "Ad systems can now insert ads on over fifty cable networks with another 25 networks scheduled for third quarter. Our goal is to have the ability to insert ads on every major cable network and to make our systems accessible by all advertisers. With over 70,000 homes installed we have begun building a truly global advertising media previously untapped by advertisers."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=20464924

How likely is it that J. Michael Heil has been pulling-our-legs for more than 15 years? My crystal ball shows otherwise...

AATV (ask) .495 - adding/plunging while someone continues giving shares away? Is anyone joining me in this venture or am I flying solo here while we await Q4 results anyday now?

Q3 - Revenue $3.5M / EPS .035

Q4 - Revenue $5.7M / EPS ???

Revenue recorded for the fourth quarter of 2020 exceeded $5.71 million, for an increase of more than double from that prior largest quarter.

https://www.otcmarkets.com/stock/AATV/news/Adaptive-Ad-Systems-Announces-Record-Revenue-For-4th-Quarter-2020-Exceeding-571-Million?id=289072

I've sidelined all shorting-strategies while trying to maintain a large cash position in search of the more lucrative, much less risky, and in my value-analysis-wheelhouse dip-buying oppurtunities.

I just can't figure out how to make any "sizeable" gain with any short strategy - all high-risk / low-reward imo? Using SFIX as an example...

https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=sfix&insttype=&freq=1&show=&time=7

...this flyingpig finally got some deserved come-uppins but where would one have started shorting and how would one have obtained any "sizeable" gain?

"...The Company plans to begin trials by the end of Q2 2020..."

https://www.otcmarkets.com/stock/NBIO/profile

Still not updated!!! Seriously Clark?

Sold a ton at .09's - .08's trimming back to a more comfortable flipping position as we await this CEO (or a NEW CEO perhaps)...one that's willing to exhibit even an iota of enthusiasm?

VBIV 3.35 - receives grant from CEPI:

On March 9, 2021, Variation Biotechnologies Inc., a Canadian federal corporation and a wholly-owned subsidiary of VBI Vaccines Inc. (together with Variation Biotechnologies Inc., the “Company”) and the Coalition for Epidemic Preparedness Innovations (the “CEPI”) entered into a funding agreement (the “Agreement”), pursuant to which CEPI will provide up to $33 million to support the advancement of the Company’s enveloped virus like particle (“eVLP”) vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant first identified in South Africa. The Company is to use commercially reasonable efforts to undertake the development of such vaccine candidates.

https://ih.advfn.com/stock-market/NASDAQ/vbi-vaccines-VBIV/stock-news/84542798/current-report-filing-8-k

Doubled down in premarket and anticipating some extreme covered-call opps this morning on this news...

VBIV 3.35 - receives grant from CEPI:

On March 9, 2021, Variation Biotechnologies Inc., a Canadian federal corporation and a wholly-owned subsidiary of VBI Vaccines Inc. (together with Variation Biotechnologies Inc., the “Company”) and the Coalition for Epidemic Preparedness Innovations (the “CEPI”) entered into a funding agreement (the “Agreement”), pursuant to which CEPI will provide up to $33 million to support the advancement of the Company’s enveloped virus like particle (“eVLP”) vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant first identified in South Africa. The Company is to use commercially reasonable efforts to undertake the development of such vaccine candidates.

https://ih.advfn.com/stock-market/NASDAQ/vbi-vaccines-VBIV/stock-news/84542798/current-report-filing-8-k

You mean a 'special-purpose-acquisition-company' might possibly fail in their special-purpose-acquisition??? Who knew...

RIGL 4.06 - filed 10K yesterday afterclose and got totally ignored. This one has multiple HOT HOT HOT irons in the fire and getting zero respect for the LLY upfront payment of $125M...ie - they'll have no nearterm need for financing (printing new shares) and in the Q1 report upcoming very soon, we can look forward to showing a whopping profit...

https://www.marketwatch.com/press-release/rigel-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-update-2021-03-02?siteid=bigcharts&dist=bigcharts&tesla=y

...really like this one for longterm and with any pop in pps, the option premiums could once again become lucrative

Covered call premiums are especially high on my 'bread-n-butter' cashfat-biobusts. Having the time of my life with all trading per se mostly moved to the backburner...

See CLBS, HEPA, TRVN, TYME...

the new trading - "rolling" weekly or monthly covered calls

OCGN 12.20 - also added. Covered call premiums at 20%+ for 2-1/2 weeks (March 19 expiration). You gotta love these robinhooligans, no?

VXRT - February 25, 2021, 3:01 PM...VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021

https://finance.yahoo.com/news/vaxart-provides-business-reports-fourth-210100371.html

Long term story here is just fine...

The data show that Pritumumab ("PTB") successfully blocked 80% of viral entry into cells. Based on these results, PTB will be advanced to laboratory-based animal studies.

https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Announces-Successful-Pritumumab-In-Vitro-Trial-Data-in-Collaborative-Covid-19-Treatment-Study-with-Syrac?id=290256

It's the short-term rinkydinkystinkypinky way NBIO management treats we retail shareholders with information, lack of information.

In layman-speak: If it trades rinkydinkystinkypinky then trade it like it's a rinkydinkystinkypinky

Long term story here is just fine...

The data show that Pritumumab ("PTB") successfully blocked 80% of viral entry into cells. Based on these results, PTB will be advanced to laboratory-based animal studies.

https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Announces-Successful-Pritumumab-In-Vitro-Trial-Data-in-Collaborative-Covid-19-Treatment-Study-with-Syrac?id=290256

It's the short-term rinkydinkystinkypinky way NBIO management treats we retail shareholders with information, lack of information.

In layman-speak: If it trades rinkydinkystinkypinky then trade it like it's a rinkydinkystinkypinky

"scheduled to begin in February, 2021"...surely we outsider-shareholders will receive an update either today or tomorrow???

Otherwise...rinkydinky is as rinkydinky does

providing evidentiary links in support of verbage will sometimes induce "chatter", no?

CLBS 1.88 - bought a ton more this morning and sold the March-$2-calls at .25 and .30. They also recently sold a bunch in secondary at $2.

Joined you in some high-premium-OCGN, thanks. Will this 'high-premiums' party ever end...?

This will take us through Phase I/II clinical trials which are scheduled to begin in February, 2021.

I'm laying the current odds at 50/50 they whiff on this...